Recent research shows that ubrogepant, a drug typically used to treat migraine headaches, is also effective against non-headache symptoms associated with migraine, such as fatigue and light sensitivity. A phase III clinical trial involved 438 participants who experienced prodromal symptoms before migraines. The results suggest that taking ubrogepant can improve concentration and alleviate discomfort during the prodromal phase, which is often ignored in migraine treatment. This finding could significantly enhance the quality of life for migraine sufferers by addressing early symptoms more effectively.
The study highlights that ubrogepant, a drug designed for migraine relief, can also effectively reduce debilitating prodromal symptoms such as fatigue and brain fog.
According to the trial, ubrogepant could potentially alleviate debilitating non-headache symptoms that many experience before migraine onset, thus improving overall quality of life.
Collection
[
|
...
]